Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study record now shows a Completed status with updated Study Status and Recruitment Status, and new References and Contacts/Locations sections have been added. The previous government-funding operating status notice has been removed.SummaryDifference1.0%

- Check21 days agoChange DetectedAdded a site-wide funding-status notice and updated the revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check28 days agoChange DetectedThe history page now displays a glossary, uses green/red highlights to show additions and deletions, and updates the revision label to v3.4.0 (replacing v3.3.4), with minor textual tweaks like capitalization of 'FEAR Act Data'.SummaryDifference0.6%

- Check64 days agoChange DetectedFooter metadata updated with Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check86 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to study content or page functionality are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check93 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1 on the page footer; this change does not affect study information or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.